๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
180
Hangzhou
2025-12-29
Recruiting
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07376642Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1
30
Beijing, Zhengzhou, Hangzhou
2025-12-29
Recruiting
The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Bronchoscopy
NCT07389083Hypoxia, Pulmonary Nodule, Pulmonary Infection
First Affiliated Hospital of Zhejiang University
Not applicable
50
Hangzhou
2025-12-28
Recruiting
Single-cell and Spatial Transcriptomic Profiling of Gingival Tissues in Aggressive and Chronic Periodontitis: Deciphering Cellular Heterogeneity and Inflammatory Microenvironment Features
NCT07487272Periodontis, Aggressive Periodontitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
9
Hangzhou
2025-12-26
Recruiting
Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE
NCT07268560Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Sir Run Run Shaw Hospital
Observational
100
Nanchang, Hangzhou
2025-12-25
Recruiting
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
NCT07340398HER2-positive Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
200
Hangzhou
2025-12-25
Recruiting
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
NCT07538648Cancer
Zhejiang Cancer Hospital
Phase 1
400
Hangzhou
2025-12-24
Recruiting
Bioequivalence Study of BGM0504 Injection
NCT07382908Overweight/Obesity
BrightGene Bio-Medical Technology Co., Ltd.
Phase 1
144
Hangzhou
2025-12-23
Recruiting
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
NCT07307560Hypoxia, Esophageal Cancer, Gastric Cancer (Diagnosis), Obstructive Sleep Apnea (OSA)
Zhejiang University
Not applicable
600
Hangzhou, Jiaxing, Quzhou
2025-12-21
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Not yet open
Comparing the Therapeutic Efficacy of Extended Isthmusectomy Versus Total Thyroidectomy for Isthmus Tumors of the Thyroid
NCT07274605Thymectomy, Thyroid Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
520
Hangzhou
2025-12-19
Recruiting
A Study of Picankibart in Patients With Active Psoriatic Arthritis
NCT07295509Psoriatic Arthritis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3
222
Hangzhou
2025-12-18
Active, closed
Twelve-lead Wearable Holter,MRI,CT,X-ray,Echocardiography
NCT07714109Cardiac Arrhythmia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2025-12-18
Recruiting
Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A Prospective Multicenter Single-Arm Study
NCT07328243Thyroid Cancer Patients, Lymph Node Metastasis
Tian'an Jiang
Not applicable
85
Guangzhou, Hangzhou
2025-12-17
Recruiting
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
NCT07442513Hematopoietic Stem Cell Transplantation, Thrombocytopenia
First Affiliated Hospital of Zhejiang University
Phase 3
404
Hangzhou
2025-12-16
Not yet open
Site Preservation Was Performed Through an Open Healing Oral Restorative Membrane
NCT07334067Site Preservation, Soft Tissue Healing, Anterior Dental Aesthetic Area
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
40
Hangzhou
2025-12-15
Active, closed
T Cell Receptor Gene-Engineered and Dominant Negative TGF-ฮฒ Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT07474168Tumor
Zhejiang University
Phase 1
9
Hangzhou
2025-12-15
Recruiting
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
NCT07716189Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
74
Hangzhou
2025-12-12
Recruiting
Epidural Spinal Cord Stimulation for Restoring Walking in Spinal Cord Injury
NCT07306052Spinal Cord Injuries (SCI)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
12
Hangzhou
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound
NCT07716228Nausea and Vomiting Caused by Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
74
Hangzhou
2025-12-12
Recruiting
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide
NCT07716176Nausea and Vomiting Caused by Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
74
Hangzhou
2025-12-12
Recruiting
Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
NCT07263451Breast Cancer
Tian'an Jiang
Not applicable
24
Hangzhou
2025-12-11
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shijiazhuang, Tianjin
2025-12-11
Not yet open
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
NCT07297875Achondroplasia
Abbisko Therapeutics Co, Ltd
Phase 1/2
110
Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou
2025-12-10
Recruiting
A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders
NCT06904027Urea Cycle Disorders
Tongji Hospital
Observational
40
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2025-12-09
Recruiting
Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Social Anxiety Disorder
NCT07466277Social Anxiety Disorder (SAD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-12-09
Recruiting
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.
Phase 2
30
Beijing, Harbin, Hangzhou
2025-12-08
Recruiting
Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine
NCT07263295Diaphragmatic Function, Metacarpal Fracture, Radius Fracture, Peripheral Nerve Neurolysis
Zhejiang University
Not applicable
120
Hangzhou
2025-12-05
Not yet open
Scalp Acupuncture Combined With rTMS for Upper Limb Motor Dysfunction in Stroke: A Brain Network Study
NCT07210944Upper Extremity, Acupuncture Therapy, Stroke, Transcranial Magnetic Stimulation Repetitive
Debiao Kong
Not applicable
44
Hangzhou
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
NCT07255404Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07232849Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
100
Shanghai, Hangzhou
2025-12-04
Recruiting
Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
NCT07283315Paediatric B Cell-related Autoimmune Diseases, Autoimmune Diseases, CAR
The Children's Hospital of Zhejiang University School of Medicine
Phase EARLY_PHASE1
12
Hangzhou
2025-12-03
Recruiting
First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)
NCT07285889Acute Graft Versus Host Disease
First Affiliated Hospital of Zhejiang University
Phase 1/2
35
Hangzhou
2025-12-03
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
Pfizer
Phase 3
500
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
NCT07306299Glioma, High Grade
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
10
Hangzhou
2025-12-01
Recruiting
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
NCT07670026Glioblastoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
31
Hangzhou
2025-12-01
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT07305116Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
15
Hangzhou
2025-12-01
Recruiting
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
NCT07263906Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hangzhou
2025-12-01
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer๏ผˆNSCLC๏ผ‰
NCT07388771NSCLC, Neoadjuvant Therapy
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Not yet open
Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction
NCT07250152Myocardial Infarction (MI)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,544
Hangzhou
2025-12-01
Not yet open
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
NCT07244965LOCALLY ADVANCED CERVICAL CANCERS
Women's Hospital School Of Medicine Zhejiang University
Phase 2
42
Hangzhou
2025-12-01
Not yet open
A Phase โ… /โ…กa Study of SNUG01 in Adult Subjects With ALS
NCT07169175Amyotrophic Lateral Sclerosis (ALS)
SineuGene Therapeutics Co., Ltd.
Phase 1/2
21
Beijing, Fuzhou, Hangzhou
2025-12-01
Recruiting
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
NCT07243691Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Not applicable
33
Hangzhou
2025-12-01
Recruiting
Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
NCT07252986Breast, Breast Cancer, Pathology
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
2,000
Hangzhou
2025-12-01
Recruiting
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
NCT07235384Atopic Dermatitis (AD)
Zai Lab (Shanghai) Co., Ltd.
Phase 1
84
Beijing, Jinan, Shanghai, Hangzhou
2025-12-01
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
NCT07257640Hematologic Diseases, Neoplasms
Zhejiang University
Phase 1
20
Hangzhou
2025-11-30
Recruiting
A Multicenter Study of CAR-T Cells in Primary Ph+All
NCT07252336ALL
Zhejiang University
Phase 2
50
Hangzhou
2025-11-30
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Changde, Guangzhou, Hangzhou, Jiangmen, Luoyang
2025-11-28
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 3
31
Hangzhou, Beijing
2025-11-27
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Baotou, Beijing, Guangzhou, Hangzhou, Nanchang, Shenzhen
2025-11-26
Recruiting
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide
NCT07537699Nausea and Vomiting Caused by Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-11-25
Recruiting
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
NCT07537673Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-11-25
Recruiting
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel
NCT07537660Nausea and Vomiting Caused by Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-11-25
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Not yet open
Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease
NCT07250685PD - Parkinson's Disease
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
Longitudinal Follow-up and Health-Related Outcomes in Liver Transplant Recipients and Living Donors
NCT07301853Living Donor Liver Transplantation Recipients, Deceased Donor Liver Transplantation Recipients, Living Liver Donor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
9,999
Hangzhou
2025-11-24
Recruiting
A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.
NCT07059871AD - Alzheimer's Disease, Sarcopenia, Asthenia
Zhejiang Hospital
Not applicable
200
Hangzhou
2025-11-23
Recruiting
Asymptomatic TB With Innovative Modified Short-course Regimens
NCT06153069Tuberculosis
Huashan Hospital
Phase 4
426
Beijing, Liupanshui, Nayong, Shanghai, Hangzhou
2025-11-21
Not yet open
Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication๏ผˆFrequency Adjusted Same-dose Therapy for H. Pylori๏ผ‰
NCT07242443HELICOBACTER PYLORI INFECTIONS
First People's Hospital of Hangzhou
Phase 4
240
Hangzhou
2025-11-20
Recruiting
Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients
NCT07252102Liver Cirrhosis, Polyps of Colon, Gastrointestinal Dysfunction
Zhejiang University
Not applicable
450
Shenzhen, Hangzhou
2025-11-20
Recruiting
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
NCT07231211Solid Tumors
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 1/2
258
Hangzhou
2025-11-20
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Beijing, Chongqing, Guangzhou, Wuhan, Hangzhou
2025-11-19
Recruiting
Transcutaneous Electrical Acupoint Stimulation for Postoperative Urinary Retention After Radical Surgery for Cervical Cancer
NCT07235371Postoperative Urinary Retention (POUR)
Lu Chao
Not applicable
76
Hangzhou
2025-11-18
Recruiting
Evaluating Presbyopia-Correcting IOLs in Complex Cataract Cases With Anterior Segment Abnormalities
NCT07321756Lens Diseases
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
320
Hangzhou
2025-11-17
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xiโ€™an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Not yet open
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
NCT07244666Glioblastoma (GBM)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase EARLY_PHASE1
36
Hangzhou
2025-11-15
Recruiting
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
NCT07235930Non-Resectable Pancreas Carcinoma
Zhejiang Cancer Hospital
Phase 3
292
Hangzhou
2025-11-15
Active, closed
Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal TENS Device for Migraine Treatment
NCT07451158Migraine
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Hangzhou
2025-11-15
Recruiting
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
NCT07244094Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Changchun, Tianjin, Hangzhou
2025-11-15
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
Study of LW231 in Participants With Chronic Hepatitis B
NCT07179575Chronic HBV Infection
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Phase 1/2
270
Hangzhou
2025-11-11
Recruiting
Effect of Deep Analgosedation vs. Endotracheal Intubation General Anesthesia on on Perioperative Sedation Related Adverse Events in Elderly ERCP Patients
NCT07017283Biliary and Pancreatic Diseases, Endoscopic Retrograde Cholangiopancreatography (ERCP)
Gang Chen
Not applicable
170
Hangzhou
2025-11-10
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Recruiting
Exploratory Study of UX-GIP001 Cell Therapy in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT07244328Epilepsy, MTLE
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase EARLY_PHASE1
6
Hangzhou
2025-11-10
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413Idiopathic Pulmonary Fibrosis(IPF)
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283Nonsegmental Vitiligo
Takeda
Phase 2
200
Wuhan, Xi'an, Shanghai, Kunming, Hangzhou
2025-11-03
Recruiting
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
NCT07247396Peritoneal Metastases From Colorectal Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
12
Hangzhou
2025-11-03
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
NCT07325630IBI363 + Chemotherapy
Zhejiang Cancer Hospital
Phase 2
60
Hangzhou
2025-11-03
Recruiting
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
NCT07359586Gastric Cancer, Hepatic Carcinoma, Pulmonary Carcinoma, Pancreatic Carcinoma
Zhejiang University
Observational
1,200
Hangzhou
2025-11-01
Recruiting
Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders
NCT07479758Major Depressive Disorder (MDD), Schizophrenia, Bipolar Disorder, Severe Mental Disorders
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
320
Hangzhou
2025-11-01
Recruiting
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
NCT07617246Esophagus Cancer, Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
120
Hangzhou
2025-11-01
Recruiting
The Efficacy of Specific Immunotherapy Guided by Component-Resolved Diagnosis for Dust Mite Allergens in Chinese Pediatric Patients With Rhinitis and/or Asthma
NCT07452380Allergic Rhinitis Due to House Dust Mite
The Children's Hospital of Zhejiang University School of Medicine
Observational
1,000
Hangzhou
2025-11-01
Recruiting
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
NCT07417800Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
11,000
Hangzhou
2025-11-01
Active, closed
Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional Data
NCT07741552Graft Rejection, Kidney Transplantation, Glomerulonephritis, Polyomavirus Infections
Chen Dajin
Observational
1,000
Hangzhou
2025-11-01
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Rows per page Showing 401–500 of 1812
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.